West Pharma (WST) Tops Q4 EPS by 1c, Revenues Miss; Offers FY19 EPS Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks gain, oil prices slide
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
West Announces Fourth-Quarter and Full-Year 2018 Results
February 14, 2019 6:00 AM ESTEXTON, Pa., Feb. 14, 2019 /PRNewswire/ --Â West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter and full-year 2018 and provided financial guidance for full-year 2019.Â
Executive Summary
Fourth-quarter 2018 reported net sales were $422.5 million, representing growth of 1.7% over last year's period and constant-currency, organic sales growth of 3.6%. Fourth-quarter 2018 reported net sales included a... More